123-I Ioflupane (Datscan®) presynaptic nigrostriatal imaging in patients withmovement disorders

Brazilian Archives of Biology and Technology

Volumn 48, Issue SPECIL ISS. 2, 2005, Pages 115-126

  Castrejón, Angel Soriano ^a   Vicente, Ana María García ^a   Romera, Montserrat Cortés ^a   Cano, Julia Vaamonde ^a   Marina, Sonia Rodado ^a   García, Victor Manuel Poblete ^a   Solís, Sebastián Ruiz ^a   Rubio, María del Prado Talavera ^a  

^a Ciudad Real General Hospital   (Spain)

Author keywords

123 I Ioflupane; Dopamine transporter imaging; Movement disorders; Parkinson's disease

Indexed keywords

EID: 77955530998     PISSN: 15168913     EISSN: 16784324     Source Type: Journal    
DOI: 10.1590/S1516-89132005000700017     Document Type: Article

References (94)

1. Ahlskog, J. E. (1999), The effect of dopamine agonist therapy on dopamine transporter imaging in Parkinson's disease. Mov Disord., 14, 940-946.
2. Antonini, A. (1997). Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain., 120, 2187-2195.
3. Allard, P. (1989), Age-correlated loss of dopamine uptake sites with (3H)GBR-12935 in human putamen. Neurobiol Aging., 10, 661-664.
4. Alvarez, G.L. (2001), SPECT en la enfermedad de Parkinson y otros trastornos del movimiento. Rev Mexic de Neurociencia, 2, 169-175.
5. Asenbaum, S. (1997), Imaging of dopamine transporters with iodine-123 B-CIT and SPECT in Parkinson's disease. J Nucl Med., 38, 1-6.
6. Baldereshi, M. (2000), Parkinson's disease and parkinsonism in a longitudinal study. Two fold higher incidence in men. Neurology, 55, 1358-63.
7. Benamer, T.S. (2000), Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord., 15, 503-510.
8. Benito-León, J. (2003), Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord, 18, 267-274.
9. Booij, J. (2001), The clinical benefit of imaging striatal dopamine transporters with [123I] FP-CIT SPET in differentiating patients with presynaptic parkinsonism from other forms of parkinsonism. Eur J Nucl Med., 28, 266-272.
10. Booij, J. (1999), Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med., 26, 171-182.
11. Bower, J.H. (2002), Clinical correlates of the pathology underlying parkinsonism: a population perspective. Mov Disor., 17, 910-916.
12. Brücke, T. (1997), Measurement of dopaminergic degeneration in Parkinson's disease with 123-I beta- CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm., 50, 9-24.
13. Byrne, E.J. (1989). Diffuse Lewy body disease: clinical features in 15 cases. J Neurol Neurosurg Psychiatry., 52, 709-717.
14. Catafau, A.M. (2004). Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord., 19, 1175-1182.
15. Chang, C.M, (1992), Vascular pseudoparkinsonism. Acta Neurol Scan., 86, 588-592.
16. Demirkiran, M. (2001), Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand., 104, 63-67.
17. De Keyser, J. D. (1990), Age related changes in the human nigrostriatal dopaminergic system. Ann Neurol., 27, 157-161.
18. De Rijk, M.C. (1997), Prevalence of parkinsonism and parkinson's disease in Europe: the Europarkinson Collaborative Study. J Neurol Neurosurg Psyquiatry., 62,10-15.
19. 99mTc-ECD and 123-I beta- CIT SPECT in dementia of the Alzheimer type and diffuse Lewy body disease, Eur J Nucl Med., 24, 320-325.
20. Dubinsky, R.M. (1987), Progressive supranuclear palsy and the multi-infartc state. Neurology., 37, 570-576.
21. Eidelberg, D. (1995), Early differential diagnosis of Parkinson's disease with 18-F FDG and positron emission tomography. Neurology., 45, 1995-2004.
22. Fearnley, J. (1991), Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain., 114, 2283-2301.
23. Foltynie, T. (2002),Vascular parkinsonism: a review of the precision and frequency of the diagnosis. Neuroepidemiology, 21, 1-7.
24. Forstl, H. (1993), The Lewy-body variant of Alzheimer's disease. Clinical and pathological findings. Br J Psychiatry, 162, 385-392.
25. García Vicente, A.M. (2004), Utilidad de la imagen de transportadores de dopamina (SPECT cerebral con Ioflupano-I-123) en la valoración de los trastornos del movimiento. Rev Esp Med Nucl., 23, 245-252.
26. García Vicente, A. M. (2005), SPECT con Ioflupano I- 123 en la catalogación de pacientes con síndrome parkinsoniano y vasculopatía cerebral. Rev Esp Med Nucl. (in press).
27. Gerschlager, W. (2002), 123-I beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord., 17, 518-523.
28. Gershanik, O.S. (1993), Drug-induced movement disorders. Curr Opin Neurol Neurosurg., 6, 369-76.
29. Gwinn, K. (1998), The Michigan kindred: a large family with Parkinson's disease. Mov Disord., 13, 60-5.
30. Hamano, T. (2000), Dopamine transporter SPECT in patients with Parkinson's disease. Kaku Igaku., 37, 125-9.
31. Hughes, A. J. (1992), Accuracy of clinical diagnosis of idiopatic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55, 181-4.
32. Innis, R. B. (1993), Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natk Acad Scl., 90, 11965-11969.
33. Innis, R. B. (1999), Effect of treatment with Ldopa/ carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with 123 beta CIT. Mov Disord., 14, 436-442.
34. Jellinger, K.A. (2003), Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol., 105, 415-419.
35. Jellinger, K. A. (1996), Parkinsonism due to Binswanger's subcortical arteriosclerotic encephalopathy. Mov Disord., 11, 461-462.
36. Jeon, B.S. (1998), Dopamine transporter density measured by 123 I beta-CIT SPECT is normal in DOPA-responsive dystonia. Ann Neurol., 43, 792-800.
37. Kaufman, M.J. (1991), Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's diseased striatum. Synapse, 9, 43-49.
38. Kish, S.J. (1985), Progresive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitters markers. Ann Neurol, 18, 530-536.
39. Lavalaye, J. (2000), Effect of age and gender on dopamine transporter imaging with 123-I-FP-CIT SPECT in healthy volunteers. Eur J Nucl Med, 27, 867-869.
40. Lorberboym, M. (2004), 123I-FP-CIT SPECT imaging of dopamine transporters in patients with cerebrovascular disease and clinical diagnosis of vascular parkinsonism. J NuclMed., 45, 1688-1693.
41. Lou, J. (1991),Essential tremor: clinical correlates in 350 patients. Neurology, 41,324-238.
42. Mancardi, G.L. (1988),Lacunae and cribriform cavities of the brain. Correlations with pseudobulbar palsy and parkinsonism. Eur Neurol., 28, 11-17.
43. Marek, K. (1996), 123 I beta-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemiparkinson's disease. Neurology, 46, 231-237.
44. Marek, K. (1997),123 I- beta CIT: assessment of progression in Parkinson's disease. Neurology., 48, 207-208.
45. Marek, K. (2001), 123 I-beta- CIT SPECT imaging assessment of the rate of Parkinson's disease progression, Neurology, 57, 2089-2094.
46. Mark, M.H. (1995), Binswanger's disease presenting as levo-dopa responsive parkinsonism: clinicopathologic study of three cases. Mov Disord., 10, 450-454.
47. Marsden, C.D. (1980), The pathophysiology of extrapyramidal side effects of neuroleptic drugs. Psychol Med., 10, 55-72.
48. Martí-Massó, J.F. (1998), Parkinsonismos secundarios. En: Jiménez-Jimenez FJ. Luquin MR, Molina JA. (eds). Tratado de los trastornos del movimiento. Madrid, 513-542.
49. Martí-Masso, J.F. (1996), Drug-induced or aggravated Parkinsonism: clinical signs and the changing pattern of implicated drugs. Neurologia, 11, 10-5.
50. Messa, C. (1998), Differential distribution of striatal 123 I beta-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single-photon emission tomography. Eur J Nucl Med., 25, 1270-1276.
51. Montastruc,J.L. (1994),Drug-induced parkinsonism: a review. Fundam Clin Pharmacol., 8, 293-306.
52. Mozley, P.D. (1996), Iodine- 123- IPT SPECT imaging of CNS dopamine transporters: nonlinear effects of normal aging on striatal uptake values. J Nucl Med., 37, 1965-1970.
53. Muñoz, E. (1998), Otras causas de parkinsonismo. En: Jiménez-Jimenez FJ. Luquin MR, Molina JA. (eds). Tratado de los trastornos del movimiento, Madrid; 543-564.
54. Murphy, D.G.M. (1992), Age-related differences in volumes of subcortical nuclei, brain matter and cerebrospinal fluid in healthy men as measured with magnetic resonance imaging. Arch Neurol., 49, 839-845.
55. Naumann, M. (1997), 123 I beta-CIT SPECT in DOPAresponsive dystonia. Mov Disord.,12, 448-451.
56. Nurmi, E. (2000), Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand 18-FCFT. Ann Neurol., 47, 804-808.
57. O'Brien, J.T,. (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol., 61, 919-925.
58. Pahwa, R. (1993), Is there a relationship between Parkinson's disease and essential tremor?. Clin Neuropharmacol., 16, 30-35.
59. Papapetropoulos, S. (2004), Effect of vascular disease on late onset Parkinson's disease. Eur J Neurol., 11, 231-235.
60. Parkinson Study Group. (2000), A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. Neurology., 55, 1540-1547.
61. Peterson, B.S. (1993), Human basal ganglia volume asymmetries on magnetic resonance images. Magn Res Imaging., 11, 493-498.
62. Piccini, P. (1995), White matter hyperintensities in Parkinson's disease: clinical correlations. Arch Neurol., 52, 191-194.
63. Pirker, W. (2002), Progression of dopaminergic degeneration in Parkinson's disease and atypical parkisonism: a longitudinal Beta-CIT SPECT study. Mov Disord., 17, 45-53.
64. Quinn, N. (1989), Multiple system atrophy-the nature of the beast. J Neurosurg Phychiatry., 52, 78-89.
65. Rajput, A. H. (1991), Accuracy of clinical diagnosis in parkinsonism- a prospective study, Can J Neurol Sci, 18, 275-278.
66. Reuck, J. (1980), Parkinsonism in patients with cerebral infarcts. Clin Neurol Neurosurg., 82, 177-185.
67. Rinne, J.O. (1995), Striatal dopamine transporters in different disability stages or Parkinson's disease studied with 123-I beta-CIT SPECT. Parkinsonism and Related Disorders, 22, 47-51.
68. Salemi, G. (1994), Prevalence of essential tremor: a door-to-door survey in Terrasini Sicily, Sicilian Neuro-Epidemiologic Study Group. Neurology, 44, 61-64.
69. Sasaki, T. (2003), SPECT imaging using 123 I beta-CIT and 123 I- IBF in extrapyramidal diseases. No To Shinkei., 55, 57-64.
70. Seibyl, J. (1995), Decreased SPECT 123 I beta-CIT striatal uptake correlates with symptom severity in idiopathic Parkinson's disease. Ann Neurol., 38, 589-598.
71. Sibon, I. (2004). Parkinsonismo vascular. J Neurology (edición española)., 2, 253-64.
72. Sibon, I. (2004), Vascular parkinsonism. Current Opin in Neurol., 17, 49-54.
73. Staffen, W. (2000), Measuring the progression of idiopathic Parkinson's disease with 123 I-BetaCIT SPECT. J Neural Transm., 107,543-552.
74. Tatsch, K. (2001), Imaging of the dopaminergic system in parkinsonism with SPET. Nucl Med Commun, 22, 819-827.
75. Tissingh, G. (1998), Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by iodine-123- I beta-CIT SPECT. J Neurol., 245, 14-20.
76. Tissingh, G. (1997) Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med., 24, 1171-1174.
77. Tolosa, E.S. (1984), Parkinsonism and basal ganglia infarcts. Neurology, 34, 1516-18.
78. Trenkwalder, C. (1995), Postural stability differentiates "lower body" from idiopatic parkinsonism. Acta Neurol Scand., 91, 444-52.
79. 99m-Tc-TRODAT-1. J Nucl Med., 42, 408-413.
80. Vaamonde, J. (2004), Estudio pre y postsináptico de la via nigroestriada mediante DATSCAN o IBZM SPECT en el diagnóstico diferencial del parkinsonismo en 75 pacientes. Neurologia, 19, 292-300.
81. Van Dyck, C.H. (1995), Age-related decline in striatal dopamine transporter binding with iodine-123-B CIT SPECT. J Nucl Med., 36, 1175-1181.
82. Varrone, A. (2001), 123-I beta CIT SPECT imaging demonstrates reduced density of striatal dopamine transportes in Parkinson's disease and multiple system atrophy. Mov Disorders., 16, 1023-1032.
83. Van Dyck, C.H. (2002), Age-related decline in dopamine transporters. Am J Geriatr Psychiatry, 10, 36-43.
84. Van Gerpen JA. (2002), Drug-induced parkinsonism. Neurolog., 8, 363-370.
85. Volkow, N.D. (1996), Dopamine transporters decrease with age. J Nucl Med., 37, 554-559.
86. Walker, Z. (1997), Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine- 123 iodobenzamide SPECT. Eur J Nucl Med., 24, 609-614.
87. Walker, Z. (2002), Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurosurg Psychiatry, 73, 134-140.
88. Walker, Z. (2004), Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease. A comparison. Neurology, 62, 1568-1572.
89. 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med., 45, 393-401.
90. Wenning, G.K. (1994), Clinical features and natural history of multiple sistem atrophy. An análisis of 100 cases. Brain., 117, 835-845.
91. Winogrodzka, A. (2003), 123 beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry, 74, 294-298.
92. Yamanouchi, H. (1997), Neurological signs and frontal white matter lesions in vascular parkinsonism. Stroke., 28, 965-969.
93. Zelnik, N. (1986), Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol., 126, 175-176.
94. Zijlmans, J.C.M. (1995), MRI in patientes with suspected vascular parkinsonism. Neurology, 45, 2183-2188.